{"id":"arexvy","rwe":[{"pmid":"41884825","year":"2026","title":"RSV vaccine development: advances and fusion protein-focused strategies.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"},{"pmid":"41833132","year":"2026","title":"Safety monitoring of health outcomes following RSVPreF3 + AS01 and RSVPreF vaccination among Medicare beneficiaries aged 65 years and older in the United States, 2023-2024.","finding":"","journal":"Vaccine","studyType":"Clinical Study"},{"pmid":"41767892","year":"2026","title":"Real-world evidence on RSV vaccine uptake, effectiveness, and safety in older adults: a systematic review and meta-analysis.","finding":"","journal":"The Lancet regional health. Europe","studyType":"Clinical Study"},{"pmid":"41685002","year":"2026","title":"Current and Emerging Strategies for the Prevention of Respiratory Syncytial Virus (RSV) Infections: A Comprehensive Review of Vaccines and Antibody Therapies.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41600801","year":"2025","title":"Crucial Obstacles and Strategies for Human RSV Pediatric Vaccine Development.","finding":"","journal":"Viruses","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Clover Biopharmaceuticals AUS Pty","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Injection site pain","drugRate":"76%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"59.9%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"59.6%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"43.6%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"28.3%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"39.8%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"35.6%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"31.7%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"23.4%","severity":"common","organSystem":""},{"effect":"Erythema","drugRate":"13.2%","severity":"common","organSystem":""},{"effect":"Swelling","drugRate":"10.4%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"33.6%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"28.9%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"27.2%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"18.1%","severity":"common","organSystem":""}],"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Clover Biopharmaceuticals AUS Pty","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AREXVY","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:58:04.616814+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:58:24.526668+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:58:16.110911+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AREXVY","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:58:16.918317+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Fusion glycoprotein F0 vaccine antigen","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:58:17.501683+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068489/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:58:17.409536+00:00"}},"allNames":["arexvy"],"offLabel":[],"synonyms":[],"timeline":[],"aiSummary":"Arexvy, developed by Clover Biopharmaceuticals AUS Pty, is a marketed drug with an unknown mechanism of action. The key composition patent for Arexvy is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.","approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Unfortunately, due to the lack of available information, the technical details of Arexvy's mechanism of action cannot be provided."},"commercial":{"revenueYear":2024,"annualRevenue":1500,"revenueSource":"GSK AR 2024"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=arexvy","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=arexvy","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:29:21.607963","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:58:24.526741+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"arexvy","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06489964","phase":"NA","title":"Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies","status":"RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-23","conditions":["Preventable Disease, Vaccine"],"enrollment":600,"completionDate":"2026-12"},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":["Lymphoma"],"enrollment":500,"completionDate":"2026-08-16"},{"nctId":"NCT07050732","phase":"PHASE2","title":"Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-12-04","conditions":["Respiratory Syncytial Virus (RSV)"],"enrollment":170,"completionDate":"2028-04"},{"nctId":"NCT06593210","phase":"PHASE3","title":"RSV Vaccine in Transplant Recipients","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-10-01","conditions":["Vaccine Response Impaired","Respiratory Syncytial Virus Infections","Immune Suppression"],"enrollment":100,"completionDate":"2026-03"},{"nctId":"NCT06077149","phase":"PHASE4","title":"Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2023-11-07","conditions":["Respiratory Syncytial Virus (RSV)"],"enrollment":152,"completionDate":"2024-11-01"},{"nctId":"NCT07203365","phase":"PHASE3","title":"RSV Immunogenicity Study in the Elderly (RISE)","status":"RECRUITING","sponsor":"Karin Karin Loré","startDate":"2025-08-25","conditions":["RSV Immunisation"],"enrollment":65,"completionDate":"2029-05-31"},{"nctId":"NCT06556147","phase":"PHASE1","title":"A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vicebio Australia Proprietary Limited","startDate":"2024-08-13","conditions":["Healthy Volunteers"],"enrollment":144,"completionDate":"2027-05"},{"nctId":"NCT06481579","phase":"PHASE2","title":"A Study of IVX-A12 in Adults Participants","status":"COMPLETED","sponsor":"Icosavax, Inc.","startDate":"2024-06-10","conditions":["Healthy Participants"],"enrollment":143,"completionDate":"2024-12-19"},{"nctId":"NCT06194318","phase":"PHASE1","title":"First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2023-12-13","conditions":["Respiratory Syncytial Virus Vaccination"],"enrollment":160,"completionDate":"2025-05-07"},{"nctId":"NCT06843317","phase":"PHASE1","title":"Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults","status":"RECRUITING","sponsor":"Clover Biopharmaceuticals USA, LLC","startDate":"2025-03-21","conditions":["RSV Infection"],"enrollment":160,"completionDate":"2026-06-03"},{"nctId":"NCT06442241","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2024-07-31","conditions":["Respiratory Syncytial Virus (RSV)","RSV Infection"],"enrollment":84,"completionDate":"2025-12-30"},{"nctId":"NCT06597916","phase":"PHASE2","title":"RSV Vaccination in Immunocompromised Patients.","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-09-19","conditions":["RSV Infection"],"enrollment":200,"completionDate":"2026-03-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL6068489"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Clover Biopharmaceuticals AUS Pty","relationship":"Original Developer"}],"publicationCount":63,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Clover Biopharmaceuticals AUS Pty","recentPublications":[{"date":"2026","pmid":"41884825","title":"RSV vaccine development: advances and fusion protein-focused strategies.","journal":"Frontiers in immunology"},{"date":"2026 Mar 14","pmid":"41833132","title":"Safety monitoring of health outcomes following RSVPreF3 + AS01 and RSVPreF vaccination among Medicare beneficiaries aged 65 years and older in the United States, 2023-2024.","journal":"Vaccine"},{"date":"2026 May","pmid":"41767892","title":"Real-world evidence on RSV vaccine uptake, effectiveness, and safety in older adults: a systematic review and meta-analysis.","journal":"The Lancet regional health. Europe"},{"date":"2026 Jan","pmid":"41685002","title":"Current and Emerging Strategies for the Prevention of Respiratory Syncytial Virus (RSV) Infections: A Comprehensive Review of Vaccines and Antibody Therapies.","journal":"Cureus"},{"date":"2025 Dec 24","pmid":"41600801","title":"Crucial Obstacles and Strategies for Human RSV Pediatric Vaccine Development.","journal":"Viruses"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"AREXVY","companyName":"Clover Biopharmaceuticals AUS Pty","companyId":"clover-biopharmaceuticals-aus-pty","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:58:24.526741+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}